CA2300433A1 - Methode pour traiter les troubles lacrymaux - Google Patents
Methode pour traiter les troubles lacrymaux Download PDFInfo
- Publication number
- CA2300433A1 CA2300433A1 CA002300433A CA2300433A CA2300433A1 CA 2300433 A1 CA2300433 A1 CA 2300433A1 CA 002300433 A CA002300433 A CA 002300433A CA 2300433 A CA2300433 A CA 2300433A CA 2300433 A1 CA2300433 A1 CA 2300433A1
- Authority
- CA
- Canada
- Prior art keywords
- botulinum toxin
- units
- botulinum
- lacrimation
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000025551 Lacrimation disease Diseases 0.000 title claims description 6
- 238000000034 method Methods 0.000 title abstract description 35
- 108030001720 Bontoxilysin Proteins 0.000 claims abstract description 57
- 229940053031 botulinum toxin Drugs 0.000 claims abstract description 42
- 230000001713 cholinergic effect Effects 0.000 claims abstract description 8
- 206010023644 Lacrimation increased Diseases 0.000 claims abstract description 7
- 230000004317 lacrimation Effects 0.000 claims abstract description 7
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 11
- 229940094657 botulinum toxin type a Drugs 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 abstract description 17
- 230000036407 pain Effects 0.000 abstract description 17
- 208000007101 Muscle Cramp Diseases 0.000 abstract description 16
- 208000005392 Spasm Diseases 0.000 abstract description 16
- 230000028327 secretion Effects 0.000 abstract description 11
- 210000003097 mucus Anatomy 0.000 abstract description 6
- 230000035900 sweating Effects 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 208000035475 disorder Diseases 0.000 abstract description 5
- 208000029578 Muscle disease Diseases 0.000 abstract description 4
- 208000021642 Muscular disease Diseases 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 210000002460 smooth muscle Anatomy 0.000 abstract description 4
- 210000002565 arteriole Anatomy 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 210000005095 gastrointestinal system Anatomy 0.000 abstract description 3
- 210000000664 rectum Anatomy 0.000 abstract description 3
- 210000005070 sphincter Anatomy 0.000 abstract description 3
- 230000002485 urinary effect Effects 0.000 abstract description 3
- 210000000232 gallbladder Anatomy 0.000 abstract description 2
- 230000004118 muscle contraction Effects 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 description 32
- 239000003053 toxin Substances 0.000 description 32
- 108700012359 toxins Proteins 0.000 description 32
- 238000011282 treatment Methods 0.000 description 23
- 210000003205 muscle Anatomy 0.000 description 22
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 206010044074 Torticollis Diseases 0.000 description 11
- 201000002849 spasmodic dystonia Diseases 0.000 description 10
- 206010067672 Spasmodic dysphonia Diseases 0.000 description 9
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 201000006517 essential tremor Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 6
- 241000193155 Clostridium botulinum Species 0.000 description 5
- 208000008454 Hyperhidrosis Diseases 0.000 description 5
- 108010069023 botulinum toxin type E Proteins 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 108700017751 botulinum toxin type C Proteins 0.000 description 4
- 108010069022 botulinum toxin type D Proteins 0.000 description 4
- 108010069038 botulinum toxin type F Proteins 0.000 description 4
- 108010069071 botulinum toxin type G Proteins 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 4
- 230000001523 saccharolytic effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000025978 Athletic injury Diseases 0.000 description 3
- 208000014094 Dystonic disease Diseases 0.000 description 3
- 241000792859 Enema Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000004350 Strabismus Diseases 0.000 description 3
- 206010043269 Tension headache Diseases 0.000 description 3
- 208000008548 Tension-Type Headache Diseases 0.000 description 3
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 3
- 238000002567 electromyography Methods 0.000 description 3
- 239000007920 enema Substances 0.000 description 3
- 229940095399 enema Drugs 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 208000018360 neuromuscular disease Diseases 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 2
- 208000003508 Botulism Diseases 0.000 description 2
- 241001112696 Clostridia Species 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 206010005159 blepharospasm Diseases 0.000 description 2
- 230000000744 blepharospasm Effects 0.000 description 2
- 229940089093 botox Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940098753 dysport Drugs 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000715 neuromuscular junction Anatomy 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 201000002851 oromandibular dystonia Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940124133 Acetylcholine release inhibitor Drugs 0.000 description 1
- 208000009017 Athetosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000186542 Clostridium baratii Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 241000186581 Clostridium novyi Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061991 Grimacing Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041738 Sports injury Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000013142 Writer cramp Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 201000002865 focal hand dystonia Diseases 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940095895 haldol Drugs 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000018197 inherited torticollis Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002182 synaptic membrane Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036977 tonic contraction Effects 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17399693A | 1993-12-28 | 1993-12-28 | |
| US08/173,996 | 1993-12-28 | ||
| CA002180011A CA2180011C (fr) | 1993-12-28 | 1994-12-16 | Toxines botulinum utilisees dans le traitement de divers troubles, et douleurs associees |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002180011A Division CA2180011C (fr) | 1993-12-28 | 1994-12-16 | Toxines botulinum utilisees dans le traitement de divers troubles, et douleurs associees |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2300433A1 true CA2300433A1 (fr) | 1995-07-06 |
Family
ID=25678525
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002300666A Expired - Lifetime CA2300666C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter la dystonie avec botulinum type b |
| CA002300464A Expired - Fee Related CA2300464C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter les maux de tetes |
| CA002300663A Expired - Fee Related CA2300663C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter la dyphagie |
| CA002300723A Abandoned CA2300723A1 (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter la douleur associe a un muscle |
| CA002300433A Abandoned CA2300433A1 (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter les troubles lacrymaux |
| CA002300771A Abandoned CA2300771A1 (fr) | 1993-12-28 | 1994-12-16 | Procede pour traiter une secretion muqueuse |
| CA002300766A Expired - Lifetime CA2300766C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter une secretion cholinergique influencee |
| CA002300451A Abandoned CA2300451A1 (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter une maladie de la valve pylorique |
| CA002300703A Expired - Lifetime CA2300703C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter la sudation excessive |
| CA002300386A Expired - Fee Related CA2300386C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter la dystonie avec des toxines botuliniques de types c, d et e |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002300666A Expired - Lifetime CA2300666C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter la dystonie avec botulinum type b |
| CA002300464A Expired - Fee Related CA2300464C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter les maux de tetes |
| CA002300663A Expired - Fee Related CA2300663C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter la dyphagie |
| CA002300723A Abandoned CA2300723A1 (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter la douleur associe a un muscle |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002300771A Abandoned CA2300771A1 (fr) | 1993-12-28 | 1994-12-16 | Procede pour traiter une secretion muqueuse |
| CA002300766A Expired - Lifetime CA2300766C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter une secretion cholinergique influencee |
| CA002300451A Abandoned CA2300451A1 (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter une maladie de la valve pylorique |
| CA002300703A Expired - Lifetime CA2300703C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter la sudation excessive |
| CA002300386A Expired - Fee Related CA2300386C (fr) | 1993-12-28 | 1994-12-16 | Methode pour traiter la dystonie avec des toxines botuliniques de types c, d et e |
Country Status (1)
| Country | Link |
|---|---|
| CA (10) | CA2300666C (fr) |
-
1994
- 1994-12-16 CA CA002300666A patent/CA2300666C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002300464A patent/CA2300464C/fr not_active Expired - Fee Related
- 1994-12-16 CA CA002300663A patent/CA2300663C/fr not_active Expired - Fee Related
- 1994-12-16 CA CA002300723A patent/CA2300723A1/fr not_active Abandoned
- 1994-12-16 CA CA002300433A patent/CA2300433A1/fr not_active Abandoned
- 1994-12-16 CA CA002300771A patent/CA2300771A1/fr not_active Abandoned
- 1994-12-16 CA CA002300766A patent/CA2300766C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002300451A patent/CA2300451A1/fr not_active Abandoned
- 1994-12-16 CA CA002300703A patent/CA2300703C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002300386A patent/CA2300386C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2300766C (fr) | 2008-10-14 |
| CA2300663A1 (fr) | 1995-07-06 |
| CA2300386A1 (fr) | 1995-07-06 |
| CA2300703A1 (fr) | 1995-07-06 |
| CA2300464C (fr) | 2001-12-11 |
| CA2300766A1 (fr) | 1995-07-06 |
| CA2300666C (fr) | 2002-04-30 |
| CA2300771A1 (fr) | 1995-07-06 |
| CA2300464A1 (fr) | 1995-07-06 |
| CA2300451A1 (fr) | 1995-07-06 |
| CA2300723A1 (fr) | 1995-07-06 |
| CA2300666A1 (fr) | 1995-07-06 |
| CA2300663C (fr) | 2003-05-06 |
| CA2300386C (fr) | 2002-04-23 |
| CA2300703C (fr) | 2001-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU688452B2 (en) | Botulinum toxins for treating various disorders and associated pain | |
| US8216995B2 (en) | Botulinum toxin treatments | |
| US8557256B2 (en) | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin | |
| CA2590293C (fr) | Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique | |
| CA2300663C (fr) | Methode pour traiter la dyphagie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |